Crane Co. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Crane Co. on January 25, 2016. The filing primarily addresses the announcement of results of operations for the quarter ended December 31, 2015, and provides a detailed update on asbestos liability claims and costs. The company is incorporated in Delaware and maintains its principal executive offices in Stamford, Connecticut.
Key Financial Metrics: Asbestos Liability and Costs
The filing does not provide general revenue, profit, or cash flow figures for the quarter; these are referenced in attached exhibits. However, specific financial data regarding asbestos litigation is provided:
- Asbestos Liability Reserve: $546 million as of December 31, 2015 (down from $894 million recorded in 2011).
- Current Portion of Liability: $75 million, representing estimated costs to be paid within the next twelve months.
- Insurance Receivable Asset: $129 million as of December 31, 2015 (estimated probable reimbursement).
- Total Costs Incurred (2015): $69.4 million (comprising $27.7 million in settlement/indemnity and $41.7 million in defense costs).
- Net Pre-tax Cash Payments (2015): $49.9 million (after $18.1 million in insurance receipts).
- Pending Claims: 41,090 active claims as of December 31, 2015.
Material Changes Versus Prior Periods
Asbestos activity showed a reduction in both claims volume and costs compared to prior years:
- Claims Volume: Ending claims decreased from 47,507 in 2014 to 41,090 in 2015. New claims filed in 2015 were 2,572, down from 2,743 in 2014.
- Costs Incurred: Total costs incurred dropped to $69.4 million in 2015, compared to $81.1 million in 2014 and $90.8 million in 2013.
- Cash Payments: Net pre-tax cash payments decreased to $49.9 million in 2015, compared to $61.3 million in 2014.
- Liability Estimate: Management determined no change to the liability estimate was warranted for the period ended December 31, 2015, as actual experience approximated assumptions.
Outlook, Risks, and Contingencies
Outlook and Methodology: The company utilizes a forecast period extending through 2021 for liability estimation. Management believes costs beyond 2021 cannot be reasonably estimated due to uncertainty. The liability estimate is driven by four interdependent factors: new mesothelioma claims, average settlement costs for mesothelioma, dismissal rates, and aggregate defense costs.
Significant Litigation Risks: Several high-value verdicts remain in various stages of appeal or settlement:
- James Poage (Missouri): $10.8 million judgment entered; company will pursue appeal.
- Ivo Peraica (New York): $10.6 million judgment entered; appeal pending.
- James Nelson (Pennsylvania): Verdict vacated by Superior Court; Supreme Court of Pennsylvania holding petition pending.
- Ronald Dummitt (New York): $4.9 million judgment affirmed; appeal to New York Court of Appeals pending.
Insurance Coverage: The company has "coverage-in-place" agreements with eleven excess insurer groups and policy buyout agreements totaling $82.5 million. Approximately 25% of the liability is estimated to be reimbursable by insurers.
Investor Verification Checklist
- Verify the specific quarterly revenue and earnings figures in the attached Press Release (Exhibit 99.1) and Financial Data Supplement (Exhibit 99.2), as they are not detailed in the 8-K text.
- Monitor the status of the James Poage and Ivo Peraica appeals, as these represent significant potential liabilities not yet fully resolved.
- Review the trend of new mesothelioma claims, as this is the primary driver of the liability estimate.
- Assess the financial viability of the excess insurers to ensure the $129 million insurance receivable asset remains collectible.
- Track legislative developments in key jurisdictions (New York, Texas, Mississippi) that may restrict claim types or affect settlement values.